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Summary.-A study is presented of the rate of metastatic spread of osteosarcoma.
The series consists of 123 tumours in long bones and 26 elsewhere in the skeleton.
All tumours occurred in otherwise normal bones and were histologically proven.
With a few stated exceptions all the cases were consecutively registered.
Both the mean disease-free interval from the time of starting treatment and the
crude survival curves are given. The long bone cases are analysed by groups
according to the method of treatment, the patient's sex, age and tumour site. There
were too few tumours of all other sites to warrant this discriminative treatment.
Whilst the results of surgical treatment are better than for radiotherapy or a com-
bined technique, the differences are not statistically significant and the information
is recorded primarily to assist the evaluation of new forms of treatment of occult
and overt metastases. Some problems in connection with such clinical trials are
discussed briefly.
THE appallingly high mortalitv of
human osteosarcoma, which in the United
Kingdom is still of the ultimate order of
85040, has largely been due to the inade-
quacy of any treatment for metastases.
Were this not so, the cure rate could be
dramatically increased to about 700o,
which is equal to the proportion of these
tumours arising in the long bones and
which usuallv provide nearly three-
quarters ofany series of cases.
During the past decade the universally
poor 5 year survival rates, which range
from nil to 3000, have stimulated an active
search for some means of restraining
metastatic spread, e.g., by pre-operative
ligation of the veins draining the tumour
site (Kuehn, Tamoney and Gossling, 1970),
by prophylactic irradiation of the lungs
(Newton, 1973: Jenkin, 1973) or by
immunotherapy (Marcove et al., 1973:
Enneking and Marsh, 1973).
A vigorous attack has also been
launched upon overt pulmonary second-
aries with chemotherapy bv Cortes et al.
(1973), Rosen et al. (1973), Jaffe (1972)
and other workers. Infusion of cvtotoxic
drugs into the bronchial arteries has been
reported by Ohno (1971) and multiple
resections for presumed solitary second-
aries have been carried out by Martini
et al. (1971).
This more aggressive attitude towards
metastatic osteosarcoma, especially of
lungs, has resulted in the situation that
now in many centres relatively few
patients-particularly juveniles-will be
treated solely by surgery or radiotherapy.
Thus the time is past for more precise
determination of the rate of metastatic
dissemination oftumours treated bv these
two original and accepted techniques.
Osteosarcoma is relatively uncommon.
The annual incidence of this tumour,
arising in otherwise normal bones, is
estimated at between 2 and 3 tumours/106
population from the records of the Bristol
Bone Tumour Registry, 1946-72 inclusive.
Applying the 1971 census figure of a total
population of 55 million in the United
Kingdom, there are only about 130 new
cases per annum in persons without other
bone disease. Allowing for the possibility
that 15°I of all local cases are missing nC. H. G. PRICE A.N_D GRACE M. JEFFR E
the Bristol registrations, the total number
would not annuallv exceed 150 new cases.
Thus it is difficult even for a major centre
to set up anv strictlv controlled trial of
these newer ancillary methods of treating
the generalized disease (British Medical
Journal, Editorial, 1971).
It is highly desirable that there should
be comparable data available in order to
evaluate at the earliest time the benefit
or otherwise of anv new methods of treat-
ing metastatic osteosarcoma. Some ofthe
more promising advances in tumour
chemotherapy, e.g. adriamycin, have seri-
ous and unpleasant side-effects which can
only be justified by the overall benefit to
the patient in terms of prolonged useful
and enjoyable life. WVhilst some infor-
mation is obtained from therapeutic trials
in laboratory- animals, rodents and other
small species do not readily produce either
spontaneous or experimental osteosarco-
mata which equal the human tumour in
their abilitv to metastasize. Moreover, at
the present time in the treatment of the
the human disease there are important
considerations other than the simple
duration of life after diagnesis and treat-
ment. Undoubtedly the most valuable
model svstem for experimental work is
canine osteosarcoma (Owen, 1973), but
this is not readilv available. Further-
more, the results ofthe effects ofcvtotoxic
drugs or immunotherapy upon tumours in
tissue culture are even more difficult to
interpret in terms of the human clinical
situation.
The results of treatment of osteo-
sarcoma have been published bv many
centres, but almost all in the form ofcrude
survival curves or 3, 5 and 10 vear survival
rates, without any indication of the
presence or absence of active local or
metastatic tumour. Some reports include
patients with Paget's disease complicated
bv osteosarcoma a form with an almost
hopeless prognosis and extremely rapid
metastatic spread (Price and Goldie, 1969).
Other series mav be biased in their selec-
tion by the tvpe of institution where they
are collected-e.g., from a children's
hospital. Likewise, differences in race,
religion or social custom may affect the
time when patients seek medical aid for a
swollen painful limb and such factors,
together with personal experience, may
influence the decision as to the method of
treatment adopted, thus possiblv deter-
mining the ultimate result.
The purpose therefore of this paper is
to record metastatic behaviour of all cases
of osteosarcoma arising in otherwise
normal bones recorded bv the Bristol Bone
Tumour Registrvduringthe vears 1946-72
inclusive. Patientsofall agesandtumours
of all sites are included but analysed in
separate groups.
Crude survival curves and estimates of
the mean disease-free interval (DFI) are
given for the following groups of cases:
Series A-123 tumours oflong bones.
Series B-26 tumours ofall other sites.
Patients known to have Paget's disease
and fibrous dysplasia were excluded, as
were one patient with multicentric osteo-
sarcoma, one with simultaneous osteo-
sarcoma offemurandbronchial carcinoma,
one patient whose tumour was treated by
resection only and 2 who received no
definitive treatment.
MATERIALS A-ND METHODS
The cases included in this study are con-
secutive registrations, all tumours being
proven histologically. For each patient the
following information has been obtained from
the case notes and radiographs:
1. The nature ofthe treatment and date of
amputation and/or commencement of radio-
therapy.
2. The time when metastases have first
been either clinically or radiographically
evident. Where this has not been recorded,
due to the absence ofregular monthly annota-
tions or radiographs, the following assump-
tions have been made: (a) The duration ofthe
DFI for each individual has been calculated
from the time of commencement of radio-
therapy or amputation, whichever has been
the earlier; (b) The maximum duration ofthe
DPI is calculated to the month when there is
first evidence of metastatic disease (either
clinical or radiological; (c) The minimum
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duration of the DFI is calculated to one
mnth folowning the last known negaire chest
film or clinical annotation of no erident
metast,ses; (d) WNhen only the date ofdeath is
recorded, it is assumed that metastases were
evident one month before that time. All
deaths within 5 years have been due to
tumour.
3. The crude survival and DFI data are
plotted at monthly intervals. The DFI
curves are shown as maximum and minimum
estimates for the number of patients without
overt metastases at any one month on the
time scale. The mean DFI curves are
con*ructedfrom the arithmetic means of maxi-
mum and minimum estimates.
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4. The cases are analysed by groups.
Series A-Long bones only.
Group Al: 53 patients treated by ampu-
tation or disarticulation. Radiotherapy or
other treatment may have been used after
amputation for subsequent local recurrence
or metastasis, but not for the primary
tumour (Fig. 1).
Group A2: 50 patients treated by radio-
therapy. Afternot less than one month from
completion of treatment, ablation of the
tumour-bearing leg was carried out for 19
patients, and similarly for an arm in 3
patients (Fig. 2).
Group A3: 20 patients treated by com-
bined radiotherapy and amputation, either
-3 AUVE
NO EVDENCE OF METASTASES
Maximum estimates
l Minimmn estimates
- -x Mean estimates
33
21 13
i- -. Q - ~~~~~16
Months from start of radiotherapy
FIG. 1.-53 cases of osteosarcoma of long bones amputated without previous irradiation.
NO EVIDENCE OF METASTASES
* Maximum estimates
M Minimum estimates
--X Mean estimates
MUONTH1S FROM AMPUTATION
FIG. 2. 50 cases of osteosarcoma of long bones treated by radical irradiation.
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20
MONTHS FROM START OF RADIOTHERAPY
FIG. 3.-20 cases of osteosarcoma of long bones amputated with pre-operative irradiation.
MONTHS FROM START OF TREATMENT
FIG. 4.-96 cases of osteoarcoma of long bones aged under 25 years.
-0 AUVE
NO EVIDENCE OF METASTASES
* Maximum estimates
* Minimum estimates
--X lMean estimates
MONTHS FROM START OF TREATMENT
FIG. 5.-27 cases of osteosarcoma of long bones aged 25 years and over.
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-0 ALUVE
NO EVIDENCE OF METASTASES
* Maximum estimates
* Minimum estimates
- -X Mean estimates
16 16 16
MONTHS FROM START OF TREATMENT
FIG. 6. 26 treated cases of osteosarcoma of other than long bones.
immediately consequent or within one month
of completion of the course of irradiation
(Fig. 3).
Comparable data of metastatic fiequency
for these three groups ofpatients are given in
Table I.
TABLE I.-Metastatic Spread of Osteo-
sarcoma of Long Bones in Different
Treatment Groups-Series A (123Cases)
Percentage with metastases
(mean estimates)
Al~ ~~~
Month
0
3
6
9
12
15
18
21
24
36
48
60
Al
amputation
(53)
27
41
51
60
67
70
72
73
743
74
77
A2 A3
radical pre-operative
radiotherapy radiotherapy
(50) (20)
6
30
51
64
73
77
81
83
84
85
89
89
17
52
72
78
83
87
89
90
90
90
90
90
These mean estimates are derived from the mean
disease-free curves of Fig. 1. 2 and 3.
Series A, of 123 cases, was also studied in
respect of age irrespective of treatment:
Juveniles under 25 years-96 (Fig. 4)
(classed as juveniles as the vast majority of
this group had not yet attained skeletal
maturity i.e. epiphyseal fusion and cessation
of all bone growth).
Mature adults over 25 years-27 (Fig. 5).
(This group implies skeletal maturity
although periosteal bone growth may con-
tinue for some time.)
Table HI shows the crude survival and
meandisease-freeratesfor123osteosarcomata
of long bones sub-divided into 68 tumours
of femur, 36 ofthe tibia and fibula and 19 of
the humerus.
Series B-All other sites (26).
Fig. 6 demonstrates the crude survival
andDFI curvesforthesepatients. Thegreat
majority were treated by radiotherapy; 2
patients, moribund when first seen, were
excluded.
RESUJLTS
Series A. Long bone tumours (Fig. 1, 2, 3)
In each group there were patients with
overt metastases at the time oftreatment.
Both at 6 and 18 months the crude sur-
vival and mean DFI are better for the
Group Al treated by surgerv alone. All
three crudesurvival and mean DFI curves
begin to level off at about 24 months, and
at 60 months the best results are still
shown by the patients treated bv surgerv
only (Al). The differences between the
groups, however, are not statistically sig-
nificant. These cases extend over a
period of 27 years (1946-72); thus in
Group A2 14 patients were treated by the
conventional 220/250 kV irradiation (until
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TABLE JJ.-Osteosarcoma of Long Bones-Series A, Comparative Results by Sites of
Tumour
Femur
(68 cases)
A
Mean
disease-
free Alive
(0°) (0O)
92
68
48
42
34
31
27
24
23
20
20
18
15
100
94
79
62
55
47
45
38
37
31
27
21
18
Tibia and Fibula
(36 cases)
A
Mean
disease-
free Alive
(00.) (,o)
97
56
41
31
28
24
23
23
23
23
23
21
100
97
89
75
61
47
39
26
26
23
23
23
21
Humerus
(19 cases)
A
Mean
disease-
fiee Alive
( ,0) ( ,o)
95
66
43
34
29
22
20
17
17
17
17
17
17
100
94
89
58
53
33
28
28
22
22
29
17
17
1956), all others received radiocobalt or
supervoltage therapy. The changing
fashion in treatment over this period is
shown in Fig. 7. In Group A3 16 patients
received 220/250 kV radiotherapy.
The effect ofpatient8' age.-Long bones
only (Figs. 4, 5).-Throughouttheduration
of 36 months after treatment, both the
crude survival and mean DFI are better
for older patients (25 years). This was
noted in a previous study (Price, 1966).
All curves again tend to flatten out 24
months from the time of completing
treatment. The differences between the
2 age groups are not statistically signifi-
cant.
The effect of sex.-Long bones only
(Table JI1).-Although the crude and
mean disease-free survival rates are slight-
ly better for females, the differences are
not statistically significant.
The effect of tumour site.-Long bones
only. Reference to Table II shows no
major differences in the mean disease-free
Niubeers ofcasestreated each year bydiffeetf regime.
e AmPUTATION without pmrevms Uiother
4]
2-
;. 6
I a 6 R IDKALRRADIATON
SR.. with _.isd mqiuin
2_ 4~~~~V
IAIPUTATION with PRE-OPERATWE IRRADIATION
2-
'6
In I'a FI
FIG.7.-Trends in treatment of osteosroma oflong bones.
Months
from start
of
treatment
0
3
6
9
12
15
18
21
24
30
36
48
60
-4
-2METASTATIC SPREAD OF OSTEOSARCOMA
TABLE III.-Osteosarcoma ofLongBones-
Series A, Comparative Results According to
Sex
74 males
Mean
disease-
free Alive
Month (0) (0o)
0 94 100
3 65 99
6 48 81
9 40 60
12 30 51
15 28 43
18 24 40
21 21 32
24 20 31
30 18 24
36 18 23
48 17 17
60 16 16
49 females
Mean
Alive
( I)
100
98
88
73
65
49
40
35
33
33
28
27
23
disease-
free
(°0)
94
78
52
43
36
31
26
24
24
24
24
22
16
rates for femoral tumours compared with
those of tibia and fibula, and tumours of
humerus, either at 24 or 60 months after
treatment. The femoral cases showed a
higher proportion of patients alive at 24
months, but at 60 months the site differ-
ences are small. Despite a general reluc-
tance to amputate a tumour-bearing arm,
the humerus cases did not fare markedly
worse than patients with tumours of the
leg.
Examination of tumour site distribu-
tion within the 3 different groups of long
bone tumours therefore indicated no
inherent bias due to these 2 factors after
a period of 12 months.
The sex distribution also appeared to
have no marked effect. Table IV shows
the sex/agelsite distribution ofGroups Al,
A2 and A3. The proportions of patients
over 25yearsofage in the 3 groups Al, A2
and A3 are respectively 28%, 18% and
1a% This preponderance of older persons
in Group Al mayhave contributedslightly
to the better results observed for the cases
treated by surgery only.
Series B. Osteosarcoma of other sites (26)
Data forthis group are shown in Fig. 6.
Three patients died oflocal spread oftheir
TABLTE JY.-Osteosarcoma Series A (123 cases), Sex, Age andSite Distribution ofTumours
ofLong Bones
A2 A3
Al Radical Pre-operative
Amputation radiotherapy radiotherapy
M F Al M F All M F All
33 20 53 27 23 50 14 6 20
2
5
11
7
1
1
1
1
17
2
1
24.4
17
11
3
2
2
5
5
1
1
2
1
1
1
1
26- 7
11
9
4
10
16
8
1
1
3
1
2
1
3
1
1
1
25-2
28
20
3
2
2
8
10
4
1
1
18.0
15
6
6
4
7
5
1
2
1
1
1
1
19-7-
13
3
6
1
6
15
15
5
3
9
1
1
1
1
18- j
28
9
12
1
4
6
1
1
1
1
22-6
7
3
4
3
3
15- 5
laa
5
7
9
1
1
1
20-5
12
3
4
1
Group
Sex
Age (years)
5-9
10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-
Mean age
Sites
Femur
Tibia
Humerus
Fibula
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tumour without evidence of metastatic
spread (1 mandible, 2 ilium). The 2
patients not included in this group
received no treatment for their tumour
(1 calvarium, 1 vertebra), both dying
from local spread within one month of
their first being seen. The more rapid
metastatic spread and shorter survival for
this group may be noted from Fig. 6. At
5 years the crude survival rate and disease-
free survivors were respectively 12% and
8%0.
Table V gives the sex/age/site distri-
bution for Series B; 69% of the patients
of this group were over 25 vears of age.
TABLE V.-Osteosarcoma of
Long Bones-Series B (26
Age and Site Distribuion
Group Male
Sex 14
Age (years)
5-9 1
10-14 1
15-19 2
20-24 1
25-29
30-34 3
35-39
40 44 1
45-49 1
50-54
55-59 2
60-64 1
65-69
70- 1
Mean age 37-5
Sites
Mandible
Maxilla
Vertebrae
Ribs
Scapula
Sacrum
Sacro-ihwa
Ilillm
Ischium
Pubis
Scaphoid (foot)
2
1
1
Of 26 patients, one was
amputation, 6 by resection
radiotherapv (11 bv 200-22
radiocobalt, 2 bysupervoltage
one bv an unrecorded techniq
DISCUSSION
Although crude survival statistics have
been published by many authors for osteo-
sarcoma, there are but few analytical
studies of the known or estimated dura-
tion ofthe mean DFI and its converse, the
rate of metastatic spread. Probably the
diagrams published by Jenkin (1973) and
Marcove et al. (1973) are those most
closely comparable with the present study.
Marcove et al. (1973) and Enneking and
Marsh (1973) in particular emphasize the
essential difficulties in constructing the
DFI curves with anything approaching
accuracy. In the absence of basic data
in past records no statistical treatment
can improve the value ofsuch information.
Other than Although in the Bristol series of long
Cases), Sex, bone tumours the best results are shown
in the surgically treated group, it is not
Female -11 suggested that these results provide any
12 26 strong argument in favour of surgery as
the preferred method of treatment. The
pros and cons of this controversy are
13: discussed at some length by Lee (1973)
1 2 and other contributors in the Colston
1 1 Papers, XXIV. Moreover, by combining
2 2 results from many sources, Trifaud and
1 2 WMarv (1972) calculate crude 5 year survi-
valrates of2100 forimmediate surgeryand
1 3 23.8% for radiotherapy with or without
9 3 surgerv. In this context there are many
1 points to be considered and evaluated
41-5 39 3 before &dciding the mode of treatment.
The data given in this paper are
presented for comparison with the results
2 4 of new methods of treatment of osteo-
1 2 sarcoma. For valid comparison the re-
2 3 sults over a 2 year period may be used, but
in order to obtain the maximum informa-
1 tion all new patients should be reviewed
2 9 at monthly intervals after treatment with
a radiograph of the chest in order to
I ascertain to the nearest month the actual
duration of the DFI. This should be
done for 24 months. As seen from all the
treated by curves given, from that time onwards the
and 19 by prognosis improves and bi- or tri-monthly
20 kV, 5 by re-examination may suffice up to the a
.therapy and year interval. This regimen not only
lue). allows an accurate estimate of the actual
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MONTHS FROM AMPUTATION
FIG. 8.-Osteosarcoma of long bones amputated Without radiotherapy. 950' confidence limits
for disease-free curve.
DFI but also provides early information
of metastatic spread, for which active
treatment should be instituted. Obvious-
Iv, great caution is required in the inter-
pretation of data derived from small
groups of cases. Fig. 8 indicates the 9500
confidence limits from small groups of 5,
10 and 25 cases estimated from the
observed data according to the formula-
p 2 times the standard error which is
calculated as
Jx q
n
where p is the percentage disease-free,
q = 100 - p, and n is the number ofcases.
(Bradford Hill, 1971). To achieve a
meaningful result in 3 years, it would be
necessarv to collect records of at least 25
patients, consisting of all available long
bone osteosarcoma cases in one year from
a population of about 15 million persons
(Fig. 8).
Any future progress in the treatment
of osteosarcoma can be anticipated only if
it is realized that probably allpatients when
first seen have nmicro-metastases. With this
practical problem in mind, a strong plea
is made for the organization ofa collabora-
tive treatment group of clinicians,
supported by radiodiagnosticians and
pathologists, to study and compare the
prophylaxis and treatment of osteosar-
coma by promising new methods, which
may include prophylactic lung irradiation
and chemotherapy', in the programme
of management.
The authors are indebted to the
numerous clinicians and other colleagues
who by referring their cases to the Bone
Tumour Registry have provided this series
of osteosarcomata collected during the
past 27 years. Their sustained interest
and help in this study have been invalu-
able, together with the advice given by
Miss E. H. L. Duncan, Medical Statistician
ofthe University ofBristol Department of
Public Health. Thanks are also due to
Mrs J. E. Nutt for much help in collecting
and maintaining case records and for
clerical assistance.
The Bristol Bone Tumour Registry is
supported by generous grants from the
Cancer Campaign for Research.
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